Sacituzumab Govitecan Shinks Tumors in One of Three Metastatic TNBC Patients, Trial Shows

Sacituzumab Govitecan Shinks Tumors in One of Three Metastatic TNBC Patients, Trial Shows
One in three women with metastatic triple-negative breast cancer — all of whom had received at least two prior treatments — saw their tumors shrink after receiving Immunomedics' investigational treatment sacituzumab govitecan as part of a Phase 1/2 trial, a new study shows. In addition to increasing response rates, the treatment also extended the time patients lived without their disease worsening, compared to previous patients given standard chemotherapy. Findings from this clinical trial were published in the New England Journal of Medicine, in the study, "Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer." “I think this drug has the potential to change practice, because the data look so compelling, even with the relatively small number of patients in the trial,” senior author Kevin Kalinsky, MD, MS, assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, said in a press release. “There’s an unmet need for patients with metastatic triple-negative breast cancer, and we see significant tumor shrinkage with this new therapy,” s
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.